Literature DB >> 12190231

Emerging technology in diabetes mellitus: glucose monitoring and new insulins.

L Raymond Reynolds1, Dennis G Karounos.   

Abstract

Modern diabetes management requires intensive self-monitoring of blood glucose levels, often coupled with a multicomponent insulin program. Recent advances include alternate site blood glucose testing devices, which facilitate more frequent sampling by individuals with diabetes. Continuous glucose monitoring through interstitial fluid analysis is now available and appears to give a more representative picture of the glycemic variations typical for type 1 diabetes. Recombinant DNA technology has led to the development of new insulin analogs that provide more physiologic insulin delivery. Inhaled and oral insulin formulations may replace multiple injections in future insulin therapy regimens.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12190231

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  1 in total

1.  Biphasic insulin Aspart 30 vs. NPH plus regular human insulin in type 2 diabetes patients; a cost-effectiveness study.

Authors:  Amir Farshchi; Rokhsareh Aghili; Maryam Oskuee; Marjan Rashed; Sina Noshad; Abbas Kebriaeezadeh; Maryam Kia; Alireza Esteghamati
Journal:  BMC Endocr Disord       Date:  2016-06-09       Impact factor: 2.763

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.